BioSpace News Archive

SYNB1891 demonstrates STING activation and target engagement in the tumor microenvironment in monotherapy cohorts

Cybin Inc. (NEO:CYBN) (“Cybin”), a life sciences company focused on psychedelic pharmaceutical therapies, is pleased to announce that it has closed on its acquisition of 100% of the shares in Adelia Therapeutics Inc. (“Adelia”) for up to CDN$20,161,575 (approximately USD$15.75 million) (the “Transaction”).

Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host the first in a series of virtual R&D events on Thursday, January 28 from 9:00 to 11:00 a.m. EST.

NurOwn® will be made available for ALS patients who completed all Phase 3 clinical trial assessments and meet specific eligibility criteria

– Sotatercept received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) in PAH in 2019 – – In the spring of 2020, sotatercept received Breakthrough Therapy designation from the FDA and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), both in PAH –

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that the first patient has been dosed in the Phase 2 BLUEPRINT trial of BLU-5937,

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Kelly A. Romano to its Board of Directors.

Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation viral immunotherapies to transform outcomes for cancer patients, today announced the appointment of Scott Canute, M.B.A. to its Board of Directors.

Astellas Venture Management (President: Kazunori Maruyama , Ph.D, “AVM”), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. and Mission Bay Capital BioLabs (“MBC BioLabs”), a lif

- Global biotech index widely followed and tracked by investors and ETFs - IMAB added to the index upon first annual review since IPO - To be effective prior to the U.S. market open on Monday, December 21, 2020 [14-December-2020] SHANGHAI and GAITHERSBURG, Md. , Dec. 14, 2020 /PRNewswire/ -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical st